Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

The Nordic approach to business builds empowerment, team spirit and engagement. But can you copy it?

Nordic-headquartered businesses occupy ten spaces on Fortune’s 100 Best Companies to Work For – Europe list, despite their countries constituting under 4% of the continent’s population.

Fortune

Wegovy, Ozempic Maker Novo Nordisk Cuts Staff At Key US Production Sites

Novo Nordisk A/S (NYSE:NVO) has reportedly laid off dozens of employees at its largest U.S. manufacturing site in North Carolina, part of a global restructuring effort under new CEO Mike Doustdar.

Benzinga

Costco Stuns Members With Half-Price Wegovy and Ozempic — But Can You Get It Without a Prescription?

Costco is now selling Wegovy and Ozempic at half price, but can members really get the drugs without a prescription? Here's everything you need to know.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Costco Stuns Members With Half-Price Wegovy and Ozempic — But Can You Get It Without a Prescription?

Costco is now selling Wegovy and Ozempic at half price, but can members really get the drugs without a prescription? Here's everything you need to know.

International Business Times UK

Major retailer to offer weight-loss jabs at discounted price

IN FULL

The Independent UK

Costco to start selling Ozempic and Wegovy at discounted prices

The Independent UK

The UK must invest in medicines – but not at any price

The UK’s science minister, Sir Patrick Vallance, has sounded the alarm over the country’s declining investment in medicines. He warned that the NHS risks losing out on important treatments and the country could lose its place at the cutting edge of medical research if spending does not recover. It comes…

The Conversation

Read news from The Economist, FT, and more,
with one subscription

Weight Loss Wars: Is Novo Nordisk’s Dominance Safe Against Eli Lilly?

As the battle for dominance heats up in the weight loss market, which stock is a better investment now?

Barchart

New drugmakers could soon offer ‘£20-a-month’ Ozempic-style weight-loss jabs

Firm Novo Nordisk’s global patent is set to expire in parts of the world from early 2026, allowing cut-price ‘own-label’ versions of Wegovy and Ozempic to be sold, according to reports

The Independent UK

Wegovy in pill form could soon be a reality as tests show it is just as effective as shots

It’s unclear how much such a pill would cost, but Novo Nordisk’s Ozempic and Wegovy shots currently go for several hundred dollars each month out of pocket

The Independent UK

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs

The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.

Benzinga

Novo Nordisk Poised For UNH-Style Comeback: New Data & AI Boost Signal Reversal

Novo Nordisk A/S (NYSE:NVO) looks ready to shake off its slump. With weight-loss pills showing blockbuster results, Ozempic proving heart-healthy benefits, and analysts flipping bullish, the stock is starting to resemble UnitedHealth Group Inc.'s (NYSE:UNH) rebound playbook.

Benzinga

Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study

Novo Nordisk A/S (NYSE:NVO) presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.

Benzinga

'Offices Need To Start Feeling A Little Bit More Like Hotels,' Behind One CBRE Exec's Approach To The Future Of In-Person Work

Within the last month, Paramount, Microsoft (NASDAQ:MSFT), and Novo Nordisk (NYSE:NVO) have announced return-to-office mandates. The companies join other major employers like Amazon (NASDAQ:AMZN), ATT (NYSE:T), and Disney (NYSE:DIS) in requiring that employees work in-person for at least half the week.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Novo Nordisk shares climb after positive anti-obesity pill results

Danish drugmaker jumps by about £9bn as trial shows ‘significant weight loss’ with tablet version of Wegovy

The Independent UK

New trial explores if weight-loss ingredient could help fight Alzheimer’s

The trials represent the first large-scale studies investigating the ingredient’s impact on the most common type of dementia

Bored Panda

Ozempic Lawsuit: Everything You Need To Know About The Latest Vision Loss Allegations

Ozempic lawsuit: Latest vision loss allegations explained. Learn about potential stomach paralysis & gastroparesis claims. Is there a connection?

The Independent UK

Weight-loss drugs help stop intrusive thoughts about food, study finds

Wegovy also was found to improve mental health, self-confidence and the development of healthier habits

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Stock Of The Day: Is The Novo Nordisk Death Spiral Finally Over?

Novo Nordisk A/S (NYSE:NVO) is trading higher on Friday. It is just below resistance around the $58 level.

Benzinga

Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment

Novo Nordisk A/S (NYSE:NVO) reportedly said on Tuesday that it intends to seek US regulatory approval for a high-dose version of its weight-loss injection Wegovy (semaglutide), another effort to counter Eli Lilly and Co. (NYSE:LLY).

Benzinga

What's Going On With Novo Nordisk Shares Monday?

Novo Nordisk A/S (NYSE:NVO) shares are trading higher Monday after the company announced European Union approval for oral semaglutide to reduce cardiovascular death, heart attack and stroke.

Benzinga

Here's Novo Nordisk's First Oral Obesity Drug In Europe With Proven Heart Health Impact

On Monday, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) approved an update to Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial.

Cycling News

Giro della Toscana: Isaac del Toro wins with solo attack across Monte Serra

Michael Storer outsprints Steff Cras for runner-up position from two-rider chase

Benzinga

Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide (Wegovy) and Eli Lilly and Co.’s (NYSE:LLY) tirzepatide (Zepbound) for obesity management.

Evening Standard

Ozempic maker to slash 9,000 jobs globally as competition intensifies

Novo Nordisk’s plans would result in around 11% of the pharmaceutical giant’s 78,400-strong workforce being axed.

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.